
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen has demonstrated significant growth in its product sales, with a reported 40% increase in 3Q25 compared to 3Q24, and 16 products achieving double-digit sales growth during the same period. The company's investment in research and development is poised to exceed 20% growth in 2025, indicating a strong commitment to innovation and market expansion. Additionally, Amgen raised its fiscal year 2025 revenue guidance to a range of $35.8-$36.6 billion, underscoring its sustained strength in established franchises and new product launches.
Bears say
The analysis indicates that Amgen is projected to experience minimal revenue growth of approximately 1% in 2026 compared to 2025, significantly impacted by anticipated declines in sales for major products like Prolia and Xgeva, which are expected to drop by about 28% and 39%, respectively. While there are emerging products with potential, such as MariTide and olpasiran, their ability to mitigate the erosion of revenue from existing therapies remains uncertain, especially given negative developments from trials. Additionally, the company faces structural challenges due to upcoming losses of exclusivity for key drug franchises, which raises concerns about the sustainability of long-term growth drivers.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares